Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in korean diabetic patients

Moo Hyun Kim, Soon Jun Hong, Kwang Soo Cha, Hun Sik Park, Shung Chull Chae, Seung Ho Hur, Hyeon Cheol Gwon, Jang Ho Bae, Do-Sun Lim

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: With the introduction of drug-eluting stents (DES), the angiographic rates of restenosis have reduced dramatically but less prominently in diabetic patients. We compared the effects of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) on 6-month angiographic and clinical outcomes in Korean diabetic patients. Method: Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned to either SES or PES in six different cardiovascular centers from April 2005 to January 2006. Patients with vessel size >2.0 mm and ≤2 vessel diseases requiring ≤2 DES implantation were included in the study. Results: Baseline clinical and angiographic characteristics were similar between the two groups. At 6-month follow-up, the late lumen loss (0.26 ± 0.76 in the SES group vs. 0.39 ± 0.92 mm in the PES group, P = 0.356) and the rate of binary restenosis (2.8% [n = 2] in the SES group vs. 6.9% [n = 5] in the PES group, P = 0.441) showed no significant differences. Rates of death (1.2% [n = 1] in the SES group vs. 1.2% [n = 1] in the PES group, P = 1.000), myocardial infarction (1.2% [n = 1] in the SES group vs. 1.2% [n = 1] in the PES group, P = 1.000), and target lesion revascularization (2.4% [n = 2] in the SES group vs. 4.8% [n = 4] in the PES group, P = 0.443) were similar in both groups during 6 months of follow-up. Conclusion: The use of either SES or PES demonstrated similar 6-month angiographic and clinical outcomes in Korean diabetic patients with coronary artery disease.

Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalJournal of Interventional Cardiology
Volume21
Issue number3
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Coronary Restenosis
Sirolimus
Paclitaxel
Stents
Drug-Eluting Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in korean diabetic patients. / Kim, Moo Hyun; Hong, Soon Jun; Cha, Kwang Soo; Park, Hun Sik; Chae, Shung Chull; Hur, Seung Ho; Gwon, Hyeon Cheol; Bae, Jang Ho; Lim, Do-Sun.

In: Journal of Interventional Cardiology, Vol. 21, No. 3, 01.06.2008, p. 225-231.

Research output: Contribution to journalArticle

Kim, Moo Hyun ; Hong, Soon Jun ; Cha, Kwang Soo ; Park, Hun Sik ; Chae, Shung Chull ; Hur, Seung Ho ; Gwon, Hyeon Cheol ; Bae, Jang Ho ; Lim, Do-Sun. / Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in korean diabetic patients. In: Journal of Interventional Cardiology. 2008 ; Vol. 21, No. 3. pp. 225-231.
@article{6c98e445106d47a8800e57e75500a127,
title = "Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in korean diabetic patients",
abstract = "Background: With the introduction of drug-eluting stents (DES), the angiographic rates of restenosis have reduced dramatically but less prominently in diabetic patients. We compared the effects of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) on 6-month angiographic and clinical outcomes in Korean diabetic patients. Method: Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned to either SES or PES in six different cardiovascular centers from April 2005 to January 2006. Patients with vessel size >2.0 mm and ≤2 vessel diseases requiring ≤2 DES implantation were included in the study. Results: Baseline clinical and angiographic characteristics were similar between the two groups. At 6-month follow-up, the late lumen loss (0.26 ± 0.76 in the SES group vs. 0.39 ± 0.92 mm in the PES group, P = 0.356) and the rate of binary restenosis (2.8{\%} [n = 2] in the SES group vs. 6.9{\%} [n = 5] in the PES group, P = 0.441) showed no significant differences. Rates of death (1.2{\%} [n = 1] in the SES group vs. 1.2{\%} [n = 1] in the PES group, P = 1.000), myocardial infarction (1.2{\%} [n = 1] in the SES group vs. 1.2{\%} [n = 1] in the PES group, P = 1.000), and target lesion revascularization (2.4{\%} [n = 2] in the SES group vs. 4.8{\%} [n = 4] in the PES group, P = 0.443) were similar in both groups during 6 months of follow-up. Conclusion: The use of either SES or PES demonstrated similar 6-month angiographic and clinical outcomes in Korean diabetic patients with coronary artery disease.",
author = "Kim, {Moo Hyun} and Hong, {Soon Jun} and Cha, {Kwang Soo} and Park, {Hun Sik} and Chae, {Shung Chull} and Hur, {Seung Ho} and Gwon, {Hyeon Cheol} and Bae, {Jang Ho} and Do-Sun Lim",
year = "2008",
month = "6",
day = "1",
doi = "10.1111/j.1540-8183.2008.00353.x",
language = "English",
volume = "21",
pages = "225--231",
journal = "Journal of Interventional Cardiology",
issn = "0896-4327",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in korean diabetic patients

AU - Kim, Moo Hyun

AU - Hong, Soon Jun

AU - Cha, Kwang Soo

AU - Park, Hun Sik

AU - Chae, Shung Chull

AU - Hur, Seung Ho

AU - Gwon, Hyeon Cheol

AU - Bae, Jang Ho

AU - Lim, Do-Sun

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Background: With the introduction of drug-eluting stents (DES), the angiographic rates of restenosis have reduced dramatically but less prominently in diabetic patients. We compared the effects of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) on 6-month angiographic and clinical outcomes in Korean diabetic patients. Method: Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned to either SES or PES in six different cardiovascular centers from April 2005 to January 2006. Patients with vessel size >2.0 mm and ≤2 vessel diseases requiring ≤2 DES implantation were included in the study. Results: Baseline clinical and angiographic characteristics were similar between the two groups. At 6-month follow-up, the late lumen loss (0.26 ± 0.76 in the SES group vs. 0.39 ± 0.92 mm in the PES group, P = 0.356) and the rate of binary restenosis (2.8% [n = 2] in the SES group vs. 6.9% [n = 5] in the PES group, P = 0.441) showed no significant differences. Rates of death (1.2% [n = 1] in the SES group vs. 1.2% [n = 1] in the PES group, P = 1.000), myocardial infarction (1.2% [n = 1] in the SES group vs. 1.2% [n = 1] in the PES group, P = 1.000), and target lesion revascularization (2.4% [n = 2] in the SES group vs. 4.8% [n = 4] in the PES group, P = 0.443) were similar in both groups during 6 months of follow-up. Conclusion: The use of either SES or PES demonstrated similar 6-month angiographic and clinical outcomes in Korean diabetic patients with coronary artery disease.

AB - Background: With the introduction of drug-eluting stents (DES), the angiographic rates of restenosis have reduced dramatically but less prominently in diabetic patients. We compared the effects of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) on 6-month angiographic and clinical outcomes in Korean diabetic patients. Method: Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned to either SES or PES in six different cardiovascular centers from April 2005 to January 2006. Patients with vessel size >2.0 mm and ≤2 vessel diseases requiring ≤2 DES implantation were included in the study. Results: Baseline clinical and angiographic characteristics were similar between the two groups. At 6-month follow-up, the late lumen loss (0.26 ± 0.76 in the SES group vs. 0.39 ± 0.92 mm in the PES group, P = 0.356) and the rate of binary restenosis (2.8% [n = 2] in the SES group vs. 6.9% [n = 5] in the PES group, P = 0.441) showed no significant differences. Rates of death (1.2% [n = 1] in the SES group vs. 1.2% [n = 1] in the PES group, P = 1.000), myocardial infarction (1.2% [n = 1] in the SES group vs. 1.2% [n = 1] in the PES group, P = 1.000), and target lesion revascularization (2.4% [n = 2] in the SES group vs. 4.8% [n = 4] in the PES group, P = 0.443) were similar in both groups during 6 months of follow-up. Conclusion: The use of either SES or PES demonstrated similar 6-month angiographic and clinical outcomes in Korean diabetic patients with coronary artery disease.

UR - http://www.scopus.com/inward/record.url?scp=43949142462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43949142462&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8183.2008.00353.x

DO - 10.1111/j.1540-8183.2008.00353.x

M3 - Article

VL - 21

SP - 225

EP - 231

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

SN - 0896-4327

IS - 3

ER -